An open-ended prospective non-randomized study involving volunteers over the age of 60.~The study will include 110 volunteers. who will receive the test drug according to the prime-boost scheme: the introduction of component 1 will be carried out on the 1st day, and component 2 - on the 21st day of the study. Outpatient monitoring will be performed during 4 visits: on the 7th, 14th, 28th, and 42nd days after the vaccine administration Also two visits will be performed in the phone contact mode for 90 and 180 days
The purpose of this study: to assess the safety, tolerability and immunogenicity of the drug Gam-COVID-Vac, a solution for intramuscular injection, at various times after vaccination in volunteers over 60 years of age